Point Therapeutics Announces Additions to Scientific and Clinical Advisory Boards
23 February 2006 - 11:30PM
Business Wire
Point Therapeutics, Inc. (NASDAQ:POTP) announced today the
appointment of two additional advisors: Charles Dinarello, M.D., to
the company's Scientific Advisory Board and Antonio Grillo-Lopez,
M.D. to the Clinical Advisory Board. Dr. Dinarello is a Professor
of Medicine at the University of Colorado School of Medicine, a
member of the U.S. National Academy of Sciences and the author of
over 500 published research articles. In addition to his active
academic research career, Dr. Dinarello has held advisory positions
with two branches of the National Institutes of Health and
positions on the Board of Governors of both the Weizmann Institute
and Ben Gurion University. Dr. Dinarello is also a director of
Techne Corporation. He received his medical degree from Yale
University and clinical training at the Massachusetts General
Hospital. Dr. Grillo-Lopez is a consultant, clinical research and
regulatory strategist to the NCI and to several biotechnology
companies. Dr. Grillo-Lopez serves as industry representative to
the Oncology Drug Advisory Committee of the FDA. He retired in 2001
from IDEC Pharmaceuticals, Inc. (now Biogen Idec, Inc.) where he
served as chief medical officer and senior vice president, medical
and regulatory affairs. He was the project clinician in the
development of Rituxan (the first monoclonal antibody for the
treatment of cancer) and supervised the clinical development of
Zevalin (the first radiolabeled antibody for the treatment of
cancer). Prior to joining IDEC, Dr. Grillo-Lopez held the position
of executive medical director for international clinical research
and development at DuPont Merck Pharmaceuticals He served as vice
president, clinical therapeutics, and director, clinical oncology
research at Warner Lambert Company's Parke-Davis Pharmaceutical
Research Division. "As Point matures in the clinic, we continue to
strengthen our advisory boards. Dr. Dinarello and Dr. Lopez are
welcome additions to the team. With two Phase 3 studies underway
and multiple on-going Phase 2 studies, we appreciate the importance
of experienced and active advisory boards to support current
clinical efforts and to help develop new strategies for our
technology," said Don Kiepert, President and CEO of Point
Therapeutics. About Point Therapeutics, Inc.: Point is a
Boston-based biopharmaceutical company developing a portfolio of
dipeptidyl peptidase (DPP) inhibitors for use in cancer, type 2
diabetes and as vaccine adjuvants. Point is currently studying its
lead product candidate, talabostat, in two Phase 3 trials in
non-small cell lung cancer. Point is also studying talabostat in
several Phase 2 trials, including as a single-agent in metastatic
melanoma, in combination with cisplatin in metastatic melanoma, in
combination with rituximab in advanced chronic lymphocytic
leukemia, and in combination with gemcitabine in metastatic
pancreatic cancer. In addition, Point's portfolio includes two
other DPP inhibitors in preclinical development--PT-630 for type 2
diabetes, and PT-510 as a vaccine adjuvant. Certain statements
contained herein are not strictly historical and are "forward
looking" statements as defined in the Private Securities Litigation
Reform Act of 1995. This information includes statements with
respect to the company's clinical development programs and the
timing of initiation and completion of its clinical trials.
Forward-looking statements are statements that are not historical
facts, and can be identified by, among other things, the use of
forward-looking language, such as "believes," "feels," "expects,"
"may," "will," "should," "seeks," "plans," "schedule to,"
"anticipates" or "intends" or the negative of those terms, or other
variations of those terms of comparable language, or by discussions
of strategy or intentions. A number of important factors could
cause actual results to differ materially from those projected or
suggested in the forward looking statement, including the risk
factors described in Point's quarterly report on Form 10-Q for the
quarter ended September 30, 2005 and from time to time in Point's
periodic and other reports filed with the Securities and Exchange
Commission.
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Point Therapeutics (MM) (NASDAQ): 0 recent articles
More Point Therapeutics, Inc. News Articles